vs
Side-by-side financial comparison of Cue Biopharma, Inc. (CUE) and SIFCO INDUSTRIES INC (SIF). Click either name above to swap in a different company.
SIFCO INDUSTRIES INC is the larger business by last-quarter revenue ($24.0M vs $21.9M, roughly 1.1× Cue Biopharma, Inc.). SIFCO INDUSTRIES INC runs the higher net margin — 7.5% vs 7.2%, a 0.2% gap on every dollar of revenue. On growth, Cue Biopharma, Inc. posted the faster year-over-year revenue change (1292.3% vs 14.8%). Over the past eight quarters, Cue Biopharma, Inc.'s revenue compounded faster (257.5% CAGR vs 8.1%).
Cue Biopharma is a clinical-stage biotechnology company focused on developing novel targeted immunotherapies for cancer, autoimmune disorders, and inflammatory diseases. Its proprietary platform enables precise T-cell activity modulation, with core operations in North America and global pharma partnerships to advance lead product candidates through clinical trials.
SIFCO Industries, Inc. (SIFCO), is a global metal component manufacturer based in Cleveland, Ohio.
CUE vs SIF — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $21.9M | $24.0M |
| Net Profit | $1.6M | $1.8M |
| Gross Margin | — | 21.6% |
| Operating Margin | 9.0% | 10.7% |
| Net Margin | 7.2% | 7.5% |
| Revenue YoY | 1292.3% | 14.8% |
| Net Profit YoY | 116.7% | 177.3% |
| EPS (diluted) | $0.05 | $0.29 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $21.9M | $24.0M | ||
| Q3 25 | $2.1M | $22.8M | ||
| Q2 25 | $3.0M | $22.1M | ||
| Q1 25 | $421.0K | $19.0M | ||
| Q4 24 | $1.6M | $20.9M | ||
| Q3 24 | $3.3M | $21.7M | ||
| Q2 24 | $2.7M | $22.0M | ||
| Q1 24 | $1.7M | $20.5M |
| Q4 25 | $1.6M | $1.8M | ||
| Q3 25 | $-7.4M | $-429.0K | ||
| Q2 25 | $-8.5M | $3.4M | ||
| Q1 25 | $-12.3M | $-1.4M | ||
| Q4 24 | — | $-2.3M | ||
| Q3 24 | $-8.7M | $-443.0K | ||
| Q2 24 | $-10.2M | $72.0K | ||
| Q1 24 | $-12.3M | $-1.6M |
| Q4 25 | — | 21.6% | ||
| Q3 25 | — | 9.6% | ||
| Q2 25 | — | 26.7% | ||
| Q1 25 | — | 8.3% | ||
| Q4 24 | — | 4.4% | ||
| Q3 24 | — | 10.7% | ||
| Q2 24 | — | 12.3% | ||
| Q1 24 | — | 7.3% |
| Q4 25 | 9.0% | 10.7% | ||
| Q3 25 | -353.4% | -1.7% | ||
| Q2 25 | -292.3% | 14.8% | ||
| Q1 25 | -2921.4% | -4.1% | ||
| Q4 24 | — | -9.2% | ||
| Q3 24 | -264.2% | -1.5% | ||
| Q2 24 | -390.6% | 0.7% | ||
| Q1 24 | -737.8% | -6.5% |
| Q4 25 | 7.2% | 7.5% | ||
| Q3 25 | -346.6% | -1.9% | ||
| Q2 25 | -287.1% | 15.4% | ||
| Q1 25 | -2911.4% | -7.3% | ||
| Q4 24 | — | -11.1% | ||
| Q3 24 | -259.6% | -2.0% | ||
| Q2 24 | -382.7% | 0.3% | ||
| Q1 24 | -719.1% | -7.8% |
| Q4 25 | $0.05 | $0.29 | ||
| Q3 25 | $-0.07 | $-0.07 | ||
| Q2 25 | $-0.09 | $0.56 | ||
| Q1 25 | $-0.17 | $-0.23 | ||
| Q4 24 | — | $-0.38 | ||
| Q3 24 | $-0.17 | $-0.07 | ||
| Q2 24 | $-0.20 | $0.01 | ||
| Q1 24 | $-0.25 | $-0.27 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $27.1M | $1.1M |
| Total DebtLower is stronger | — | $39.0K |
| Stockholders' EquityBook value | $26.4M | $38.7M |
| Total Assets | $42.2M | $74.9M |
| Debt / EquityLower = less leverage | — | 0.00× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $27.1M | $1.1M | ||
| Q3 25 | $11.7M | $491.0K | ||
| Q2 25 | $27.5M | $2.0M | ||
| Q1 25 | $13.1M | $1.9M | ||
| Q4 24 | $22.5M | $3.1M | ||
| Q3 24 | $32.4M | $1.7M | ||
| Q2 24 | $30.0M | $3.4M | ||
| Q1 24 | $41.0M | $2.5M |
| Q4 25 | — | $39.0K | ||
| Q3 25 | — | $51.0K | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $1.0M | $0 | ||
| Q2 24 | $2.0M | $3.6M | ||
| Q1 24 | $3.0M | $4.1M |
| Q4 25 | $26.4M | $38.7M | ||
| Q3 25 | $13.2M | $36.9M | ||
| Q2 25 | $18.2M | $35.8M | ||
| Q1 25 | $6.6M | $32.4M | ||
| Q4 24 | $17.5M | $33.7M | ||
| Q3 24 | $25.4M | $30.4M | ||
| Q2 24 | $21.6M | $29.8M | ||
| Q1 24 | $30.0M | $29.7M |
| Q4 25 | $42.2M | $74.9M | ||
| Q3 25 | $31.6M | $73.4M | ||
| Q2 25 | $40.7M | $77.3M | ||
| Q1 25 | $22.3M | $78.8M | ||
| Q4 24 | $32.2M | $81.0M | ||
| Q3 24 | $44.8M | $104.6M | ||
| Q2 24 | $42.3M | $106.3M | ||
| Q1 24 | $54.0M | $104.2M |
| Q4 25 | — | 0.00× | ||
| Q3 25 | — | 0.00× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.04× | 0.00× | ||
| Q2 24 | 0.09× | 0.12× | ||
| Q1 24 | 0.10× | 0.14× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.1M | $8.1M |
| Free Cash FlowOCF − Capex | — | $8.0M |
| FCF MarginFCF / Revenue | — | 33.3% |
| Capex IntensityCapex / Revenue | 0.0% | 0.4% |
| Cash ConversionOCF / Net Profit | -0.68× | 4.51× |
| TTM Free Cash FlowTrailing 4 quarters | — | $11.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.1M | $8.1M | ||
| Q3 25 | $-9.0M | $726.0K | ||
| Q2 25 | $-3.4M | $371.0K | ||
| Q1 25 | $-8.2M | $2.8M | ||
| Q4 24 | $-36.3M | $-3.8M | ||
| Q3 24 | $-7.5M | $857.0K | ||
| Q2 24 | $-10.0M | $382.0K | ||
| Q1 24 | $-9.8M | $-3.2M |
| Q4 25 | — | $8.0M | ||
| Q3 25 | — | $566.0K | ||
| Q2 25 | $-3.4M | $310.0K | ||
| Q1 25 | $-8.3M | $2.7M | ||
| Q4 24 | $-36.4M | $-3.9M | ||
| Q3 24 | $-7.5M | $580.0K | ||
| Q2 24 | $-10.0M | $-175.0K | ||
| Q1 24 | $-9.8M | $-3.9M |
| Q4 25 | — | 33.3% | ||
| Q3 25 | — | 2.5% | ||
| Q2 25 | -116.5% | 1.4% | ||
| Q1 25 | -1976.7% | 14.1% | ||
| Q4 24 | -2309.3% | -18.8% | ||
| Q3 24 | -225.7% | 2.7% | ||
| Q2 24 | -376.2% | -0.8% | ||
| Q1 24 | -573.0% | -18.9% |
| Q4 25 | 0.0% | 0.4% | ||
| Q3 25 | 0.0% | 0.7% | ||
| Q2 25 | 0.9% | 0.3% | ||
| Q1 25 | 35.6% | 0.8% | ||
| Q4 24 | 4.2% | 0.5% | ||
| Q3 24 | 0.0% | 1.3% | ||
| Q2 24 | 0.4% | 2.5% | ||
| Q1 24 | 3.2% | 3.3% |
| Q4 25 | -0.68× | 4.51× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.11× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 5.31× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CUE
| Immuno Scape Collaboration And License Agreement | $9.5M | 43% |
| BI Collaboration And License Agreement | $8.1M | 37% |
| Other | $4.3M | 20% |
SIF
| Fixed Wing Aircraft Revenue | $10.5M | 44% |
| Commercial Revenue | $8.7M | 36% |
| Commercial Product And Other Revenue | $2.8M | 12% |
| Commercial Space | $1.1M | 5% |
| Other | $840.0K | 4% |
